Glenmark’s $1 Billion Cancer Bet: Oncology Revolution Set to Ignite in FY28

In a bold strategic pivot that could redefine its future, Glenmark Pharmaceuticals is betting big on oncology—with a $1 billion milestone-laden deal for a cutting-edge Chinese cancer drug poised to hit its licensed markets by FY28. According to company leadership, this move isn’t just about adding another product; it’s the cornerstone of “Glenmark 3.0,” a high-margin, innovation-driven era set to supercharge profitability and long-term growth.

The star of this transformation is Trastuzumab Rezetecan (SHR-A1811), a HER2-targeted antibody-drug conjugate (ADC) in-licensed from China’s Hengrui Pharma in September 2025. Glenmark secured exclusive rights for key markets including India, paying an upfront $18 million and committing to potential milestone payments totaling $1.093 billion—one of the largest outlays by an Indian pharma firm for a single asset. Already approved in China for HER2-positive non-small cell lung cancer (NSCLC) and under investigation for breast cancer, the ADC represents the next frontier in precision oncology.

But Trastuzumab Rezetecan isn’t alone. Glenmark expects aumolertinib, another high-potential oncology asset, to be commercialized across multiple markets by FY28 as well. Together, these products are expected to deliver what Chairman and Managing Director Glenn Saldanha calls “meaningful gains”—not just in revenue, but in profitability. “With oncology assets, both gross and EBITDA margins are significantly higher than the core business (derma and respiratory),” Saldanha emphasized during the Q3 FY26 earnings call. “There will be definitely a margin uplift from FY28.”

This shift marks a dramatic evolution from Glenmark’s traditional stronghold in dermatology and respiratory generics. While those segments remain stable—its leading respiratory brand Ryaltris is on track to become a $100 million annual brand—the future lies in high-value, differentiated oncology therapies. The company has already guided for a 23% EBITDA margin in FY26, but investors are watching FY28 as the true inflection point.

Further amplifying Glenmark’s innovation credentials is its $1.9 billion out-licensing deal with AbbVie for the novel cancer asset ISB 2001. Dose expansion is progressing well, with Phase II trials expected to begin by end-2026, showcasing the company’s growing prowess in early-stage R&D.

Financially, Glenmark is positioning itself for this leap. As of December 2025, it sits in a net cash position of around ₹600 crore and is on track to achieve zero gross debt by March 2026—a rare feat in an industry often burdened by leverage. Meanwhile, its innovation-focused spin-off, IGI, continues to burn $70 million annually, a calculated investment in tomorrow’s pipeline.

Notably, despite India’s recent Biopharma SHAKTI initiative—a ₹10,000 crore scheme to boost biologics manufacturing—Saldanha confirmed Glenmark does not currently have in-house biologics production capacity. Yet he called the policy “definitely a positive for the industry,” leaving the door open for future strategic moves.

As FY28 approaches, all eyes will be on Glenmark’s transition from a generics player to an oncology-focused innovator. With two late-stage assets nearing commercialization, a fortress balance sheet, and a clear vision for “Glenmark 3.0,” the company is no longer just making medicine—it’s engineering a high-margin, science-led renaissance. And in the competitive world of global pharma, that’s a bet worth watching closely.